NCT06064279 2024-09-19
HAITEN-ICI
VA Office of Research and Development
Phase 1/2 Withdrawn
Clinical Trials
7 trialsNCT04799431 2023-05-09
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Withdrawn
NCT02427581 2022-03-10
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Withdrawn
NCT03068832 2021-05-25
Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Washington University School of Medicine
Phase 1 Withdrawn
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT03166254 2019-04-12
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Withdrawn
NCT02661100 2016-12-07
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn